-DOCSTART- -X- O
RATIONALE -X- _ O
: -X- _ O
Medical -X- _ B-Intervention
masks -X- _ I-Intervention
are -X- _ O
commonly -X- _ O
used -X- _ O
by -X- _ O
sick -X- _ O
individuals -X- _ B-Patient
with -X- _ I-Patient
influenza-like -X- _ I-Patient
illness -X- _ I-Patient
( -X- _ I-Patient
ILI -X- _ I-Patient
) -X- _ I-Patient
to -X- _ O
prevent -X- _ O
spread -X- _ O
of -X- _ O
infections -X- _ O
to -X- _ O
others -X- _ O
, -X- _ O
but -X- _ O
clinical -X- _ O
efficacy -X- _ O
data -X- _ O
are -X- _ O
absent. -X- _ O
OBJECTIVE -X- _ O
: -X- _ O
Determine -X- _ O
whether -X- _ O
medical -X- _ B-Intervention
mask -X- _ I-Intervention
use -X- _ I-Intervention
by -X- _ O
sick -X- _ B-Patient
individuals -X- _ I-Patient
with -X- _ I-Patient
ILI -X- _ I-Patient
protects -X- _ O
well -X- _ O
contacts -X- _ O
from -X- _ O
related -X- _ O
respiratory -X- _ O
infections. -X- _ O
SETTING -X- _ O
: -X- _ O
6 -X- _ O
major -X- _ O
hospitals -X- _ O
in -X- _ O
2 -X- _ O
districts -X- _ O
of -X- _ O
Beijing -X- _ O
, -X- _ O
China. -X- _ O
DESIGN -X- _ O
: -X- _ O
Cluster -X- _ O
randomised -X- _ O
controlled -X- _ O
trial. -X- _ O
PARTICIPANTS -X- _ O
: -X- _ O
245 -X- _ B-Patient
index -X- _ I-Patient
cases -X- _ I-Patient
with -X- _ I-Patient
ILI. -X- _ I-Patient
INTERVENTION -X- _ O
: -X- _ O
Index -X- _ O
cases -X- _ O
with -X- _ O
ILI -X- _ O
were -X- _ O
randomly -X- _ O
allocated -X- _ B-Intervention
to -X- _ I-Intervention
medical -X- _ I-Intervention
mask -X- _ I-Intervention
( -X- _ I-Intervention
n=123 -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ O
control -X- _ B-Comparison
arms -X- _ I-Comparison
( -X- _ I-Comparison
n=122 -X- _ I-Comparison
) -X- _ I-Comparison
. -X- _ O
Since -X- _ O
43 -X- _ O
index -X- _ O
cases -X- _ O
in -X- _ O
the -X- _ O
control -X- _ O
arm -X- _ O
also -X- _ O
used -X- _ O
a -X- _ O
mask -X- _ O
during -X- _ O
the -X- _ O
study -X- _ O
period -X- _ O
, -X- _ O
an -X- _ O
as-treated -X- _ O
post -X- _ O
hoc -X- _ O
analysis -X- _ O
was -X- _ O
performed -X- _ O
by -X- _ O
comparing -X- _ O
outcomes -X- _ O
among -X- _ O
household -X- _ O
members -X- _ O
of -X- _ O
index -X- _ O
cases -X- _ O
who -X- _ O
used -X- _ O
a -X- _ O
mask -X- _ O
( -X- _ O
mask -X- _ B-Intervention
group -X- _ I-Intervention
) -X- _ O
with -X- _ O
household -X- _ O
members -X- _ O
of -X- _ O
index -X- _ O
cases -X- _ O
who -X- _ O
did -X- _ O
not -X- _ O
use -X- _ O
a -X- _ O
mask -X- _ O
( -X- _ O
no-mask -X- _ B-Comparison
group -X- _ I-Comparison
) -X- _ O
. -X- _ O
MAIN -X- _ O
OUTCOME -X- _ O
MEASURE -X- _ O
: -X- _ O
Primary -X- _ O
outcomes -X- _ O
measured -X- _ O
in -X- _ O
household -X- _ O
members -X- _ O
were -X- _ O
clinical -X- _ O
respiratory -X- _ O
illness -X- _ O
, -X- _ O
ILI -X- _ O
and -X- _ O
laboratory-confirmed -X- _ O
viral -X- _ O
respiratory -X- _ O
infection. -X- _ O
RESULTS -X- _ O
: -X- _ O
In -X- _ B-Outcome
an -X- _ I-Outcome
intention-to-treat -X- _ I-Outcome
analysis -X- _ I-Outcome
, -X- _ I-Outcome
rates -X- _ I-Outcome
of -X- _ I-Outcome
clinical -X- _ I-Outcome
respiratory -X- _ I-Outcome
illness -X- _ I-Outcome
( -X- _ I-Outcome
relative -X- _ I-Outcome
risk -X- _ I-Outcome
( -X- _ I-Outcome
RR -X- _ I-Outcome
) -X- _ I-Outcome
0.61 -X- _ I-Outcome
, -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
0.18 -X- _ I-Outcome
to -X- _ I-Outcome
2.13 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
ILI -X- _ I-Outcome
( -X- _ I-Outcome
RR -X- _ I-Outcome
0.32 -X- _ I-Outcome
, -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
0.03 -X- _ I-Outcome
to -X- _ I-Outcome
3.13 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
laboratory-confirmed -X- _ I-Outcome
viral -X- _ I-Outcome
infections -X- _ I-Outcome
( -X- _ I-Outcome
RR -X- _ I-Outcome
0.97 -X- _ I-Outcome
, -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
0.06 -X- _ I-Outcome
to -X- _ I-Outcome
15.54 -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
consistently -X- _ I-Outcome
lower -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
mask -X- _ I-Outcome
arm -X- _ I-Outcome
compared -X- _ I-Outcome
with -X- _ I-Outcome
control -X- _ I-Outcome
, -X- _ I-Outcome
although -X- _ I-Outcome
not -X- _ I-Outcome
statistically -X- _ I-Outcome
significant. -X- _ I-Outcome
A -X- _ I-Outcome
post -X- _ I-Outcome
hoc -X- _ I-Outcome
comparison -X- _ I-Outcome
between -X- _ I-Outcome
the -X- _ I-Outcome
mask -X- _ I-Outcome
versus -X- _ I-Outcome
no-mask -X- _ I-Outcome
groups -X- _ I-Outcome
showed -X- _ I-Outcome
a -X- _ I-Outcome
protective -X- _ I-Outcome
effect -X- _ I-Outcome
against -X- _ I-Outcome
clinical -X- _ I-Outcome
respiratory -X- _ I-Outcome
illness -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
not -X- _ I-Outcome
against -X- _ I-Outcome
ILI -X- _ I-Outcome
and -X- _ I-Outcome
laboratory-confirmed -X- _ I-Outcome
viral -X- _ I-Outcome
respiratory -X- _ I-Outcome
infections. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
The -X- _ O
study -X- _ O
indicates -X- _ O
a -X- _ O
potential -X- _ B-Outcome
benefit -X- _ I-Outcome
of -X- _ I-Outcome
medical -X- _ I-Outcome
masks -X- _ I-Outcome
for -X- _ I-Outcome
source -X- _ I-Outcome
control -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
is -X- _ I-Outcome
limited -X- _ I-Outcome
by -X- _ I-Outcome
small -X- _ I-Outcome
sample -X- _ I-Outcome
size -X- _ I-Outcome
and -X- _ I-Outcome
low -X- _ I-Outcome
secondary -X- _ I-Outcome
attack -X- _ I-Outcome
rates. -X- _ I-Outcome
Larger -X- _ O
trials -X- _ O
are -X- _ O
needed -X- _ O
to -X- _ O
confirm -X- _ O
efficacy -X- _ O
of -X- _ O
medical -X- _ O
masks -X- _ O
as -X- _ O
source -X- _ O
control. -X- _ O
TRIAL -X- _ O
REGISTRATION -X- _ O
NUMBER -X- _ O
: -X- _ O
ACTRN12613000852752 -X- _ O
; -X- _ O
Results -X- _ O
. -X- _ O

